echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Cardiovasc Diabetol: High fibrinogen/albumin ratio in patients with type 2 diabetes is associated with poor prognosis in patients undergoing percutaneous coronary intervention

    Cardiovasc Diabetol: High fibrinogen/albumin ratio in patients with type 2 diabetes is associated with poor prognosis in patients undergoing percutaneous coronary intervention

    • Last Update: 2022-05-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Background: Inflammation plays a crucial role in the progression of coronary atherosclerosis
    .
    There is growing evidence that higher levels of inflammatory biomarkers are associated with increased adverse cardiovascular events in patients with coronary heart disease

    .
    Previous studies have shown that fibrinogen (FIB), a biomarker of inflammation and a core component of the coagulation pathway, is an independent risk factor that may predict cardiovascular events in patients with coronary heart disease

    .
    In addition, our previous findings showed that in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI), especially those with diabetes mellitus (DM), higher levels of FIB were associated with long-term all-cause and An increased risk of cardiac mortality is strongly associated
    .
    As the most abundant plasma protein, albumin is a negative acute-phase reactant produced in the liver, and its serum concentration correlates with inflammatory and hemostatic processes

    .
    In addition, serum albumin levels are inversely associated with cardiovascular mortality, and hypoalbuminemia may predict no-flow after PCI in patients with acute myocardial infarction (AMI)

    .
    Thus, both fibrinogen and albumin are important equivalents for hemorheological and inflammatory changes

    .
    Recently, several publications have confirmed that the fibrinogen/albumin ratio (FAR), including the above two indices, is a well-established prognostic factor in esophageal cancer, liver cancer, and breast cancer, and is associated with the severity of coronary artery lesions and in patients with coronary heart disease are closely related to the short-term prognosis

    .

    Background: Inflammation plays a crucial role in the progression of coronary atherosclerosis
    .
    There is growing evidence that higher levels of inflammatory biomarkers are associated with increased adverse cardiovascular events in patients with coronary heart disease

    .
    Previous studies have shown that fibrinogen (FIB), a biomarker of inflammation and a core component of the coagulation pathway, is an independent risk factor that may predict cardiovascular events in patients with coronary heart disease

    .
    In addition, our previous findings showed that in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI), especially those with diabetes mellitus (DM), higher levels of FIB were associated with long-term all-cause and An increased risk of cardiac mortality is strongly associated
    .
    As the most abundant plasma protein, albumin is a negative acute-phase reactant produced in the liver, and its serum concentration correlates with inflammatory and hemostatic processes

    .
    In addition, serum albumin levels are inversely associated with cardiovascular mortality, and hypoalbuminemia may predict no-flow after PCI in patients with acute myocardial infarction (AMI)

    .
    Thus, both fibrinogen and albumin are important equivalents for hemorheological and inflammatory changes

    .
    Recently, several publications have confirmed that the fibrinogen/albumin ratio (FAR), including the above two indices, is a well-established prognostic factor in esophageal cancer, liver cancer, and breast cancer, and is associated with the severity of coronary artery lesions and in patients with coronary heart disease are closely related to the short-term prognosis

    .
    Symptoms play a crucial role in the progression of coronary atherosclerosis
    .
    There is growing evidence that higher levels of inflammatory biomarkers are associated with increased adverse cardiovascular events in patients with coronary heart disease

    .
    Previous studies have shown that fibrinogen (FIB), a biomarker of inflammation and a core component of the coagulation pathway, is an independent risk factor that may predict cardiovascular events in patients with coronary heart disease

    .

    Inflammation is thought to be a common precursor of atherosclerosis and diabetes
    .
    Type 2 diabetes Diabetes mellitus is a well-established risk factor for coronary heart disease and has previously been shown to be strongly associated with greater atherosclerotic plaque burden and increased risk of adverse cardiovascular events

    .
    However, so far, there is insufficient literature to study the relationship between FAR levels, glucose metabolism and long-term prognosis after percutaneous coronary intervention in coronary heart disease population
    .
    In view of the above, this study aimed to evaluate the relationship between FAR and glucose metabolism markers, and to further determine the combined effect of FAR and DM on long-term major adverse cardiovascular and cerebrovascular events (MACCE) in patients with coronary heart disease undergoing PCI

    .

    Inflammation is thought to be a common precursor of atherosclerosis and diabetes
    .
    Type 2 diabetes Diabetes mellitus is a well-established risk factor for coronary heart disease and has previously been shown to be strongly associated with greater atherosclerotic plaque burden and increased risk of adverse cardiovascular events

    .
    However, so far, there is insufficient literature to study the relationship between FAR levels, glucose metabolism and long-term prognosis after percutaneous coronary intervention in coronary heart disease population
    .
    In view of the above, this study aimed to evaluate the relationship between FAR and glucose metabolism markers, and to further determine the combined effect of FAR and DM on long-term major adverse cardiovascular and cerebrovascular events (MACCE) in patients with coronary heart disease undergoing PCI

    .
    Inflammation is thought to be a common precursor of atherosclerosis and diabetes
    .
    Type 2 diabetes Diabetes mellitus is a well-established risk factor for coronary heart disease and has previously been shown to be strongly associated with greater atherosclerotic plaque burden and increased risk of adverse cardiovascular events

    .

    Methods: We consecutively enrolled 10,724 patients hospitalized for coronary heart disease undergoing PCI and followed up for major adverse cardiovascular and cerebrovascular events (MACCE), including all-cause mortality, cardiac mortality, non-fatal myocardial infarction, non-fatal Ischemic stroke and unplanned coronary revascularization
    .
    FAR was calculated using the following formula: Fibrinogen (g/L)/Albumin (g/L)

    .
    Patients were divided into high-level FAR (FAR-H) and low-level FAR (FAR-L) subgroups according to the best FAR cutoff for predicting MACCE, and further divided into FAR-H with DM and non-DM, FAR-L Four groups with DM and non-DM

    .

    Methods: We consecutively enrolled 10,724 patients hospitalized for coronary heart disease undergoing PCI and followed up for major adverse cardiovascular and cerebrovascular events (MACCE), including all-cause mortality, cardiac mortality, non-fatal myocardial infarction, non-fatal Ischemic stroke and unplanned coronary revascularization
    .
    FAR was calculated using the following formula: Fibrinogen (g/L)/Albumin (g/L)

    .
    Patients were divided into high-level FAR (FAR-H) and low-level FAR (FAR-L) subgroups according to the best FAR cutoff for predicting MACCE, and further divided into FAR-H with DM and non-DM, FAR-L Four groups with DM and non-DM

    .

    Results: 5298 patients (58.
    36±10.
    36 years, 77.
    7% male) were finally enrolled in this study

    .
    During the 5-year follow-up, a total of 1099 (20.
    7%) serious adverse events were recorded

    .
    According to the surv_cutpoint function, the best critical value for FAR is 0.
    0783

    .
    Patients with FAR-L and non-DM, FAR-H and non-DM, FAR-L and DM had a reduced risk of developing MACCEs compared with patients with FAR-H and DM [adjusted hazard ratio (HR): 0.
    75 , 95% confidence interval (CI) 0.
    64–0.
    89, P = 0.
    001HR: 0.
    78, 95% CI 0.
    66–0.
    93, P = 0.
    006HR: 0.
    81, 95% CI 0.
    68–0.
    97, P = 0.
    019, respectively

    .
    Notably, non-diabetic patients with lower FAR levels also had a lower risk of all-cause mortality and cardiac death than the FAR-H/DM group (HR: 0.
    41, 95% CI 0.
    27–0.
    63, P < 0.
    001 hazard ratio: 0.
    30 , 95% CI 0.
    17–0.
    53, P < 0.
    001, respectively)

    .
    Multivariate Cox proportional hazards regression analysis also showed that FAR-H and DM patients had the highest risk of MACCEs (trend = 0.
    005)

    .
    Furthermore, post hoc analyses revealed consistent effects of different subgroups on 5-year MACCE

    .

    Results: 5298 patients (58.
    36±10.
    36 years, 77.
    7% male) were finally enrolled in this study

    .
    During the 5-year follow-up, a total of 1099 (20.
    7%) serious adverse events were recorded

    .
    According to the surv_cutpoint function, the best critical value for FAR is 0.
    0783

    .
    Patients with FAR-L and non-DM, FAR-H and non-DM, FAR-L and DM had a reduced risk of developing MACCEs compared with patients with FAR-H and DM [adjusted hazard ratio (HR): 0.
    75 , 95% confidence interval (CI) 0.
    64–0.
    89, P = 0.
    001HR: 0.
    78, 95% CI 0.
    66–0.
    93, P = 0.
    006HR: 0.
    81, 95% CI 0.
    68–0.
    97, P = 0.
    019, respectively

    .
    Notably, non-diabetic patients with lower FAR levels also had a lower risk of all-cause mortality and cardiac death than the FAR-H/DM group (HR: 0.
    41, 95% CI 0.
    27–0.
    63, P < 0.
    001 hazard ratio: 0.
    30 , 95% CI 0.
    17–0.
    53, P < 0.
    001, respectively)

    .
    Multivariate Cox proportional hazards regression analysis also showed that FAR-H and DM patients had the highest risk of MACCEs (trend = 0.
    005)

    .
    Furthermore, post hoc analyses revealed consistent effects of different subgroups on 5-year MACCE

    .

    Figure 1 Kaplan-Meier analysis of MACCE according to different FAR levels (A), glucose metabolism status (B), and FAR levels and glucose metabolism status (C)

    Figure 1 Kaplan-Meier analysis of MACCE according to different FAR levels (A), glucose metabolism status (B), and FAR levels and glucose metabolism status (C)

    Table 1 Predictive values ​​of FAR levels and different glucose metabolic states for the primary endpoint and each component in univariate and multivariate analyses

    Table 1 Predictive values ​​of FAR levels and different glucose metabolic states for the primary endpoint and each component in univariate and multivariate analyses

    Figure 2 Hazard ratios (95% CI) for MACCE in the four groups after adjustment for age, sex, body mass index, hypertension, previous myocardial infarction, previous PCI, previous stroke, eGFR, LVEF, LM/three-vessel disease, and SYNTAX score

    Figure 2 Hazard ratios (95% CI) for MACCE in the four groups after adjustment for age, sex, body mass index, hypertension, previous myocardial infarction, previous PCI, previous stroke, eGFR, LVEF, LM/three-vessel disease, and SYNTAX score

    Figure 3 MACCE forest plots for different subgroups
    .
    Adjusted models included age, sex, body mass index, hypertension, previous myocardial infarction, previous PCI, previous stroke, eGFR, LVEF, LM/three-vessel disease, and SYNTAX score

    Figure 3 MACCE forest plots for different subgroups
    .
    Adjusted models included age, sex, body mass index, hypertension, previous myocardial infarction, previous PCI, previous stroke, eGFR, LVEF, LM/three-vessel disease, and SYNTAX score

    Conclusions: In this real cohort study, higher levels of FAR and DM were associated with poorer 5-year outcomes in patients with coronary artery disease undergoing PCI
    .
    The level of FAR may help identify high-risk individuals in this particular population, where a more precise risk assessment should be performed

    .

    Conclusions: In this real cohort study, higher levels of FAR and DM were associated with poorer 5-year outcomes in patients with coronary artery disease undergoing PCI
    .
    The level of FAR may help identify high-risk individuals in this particular population, where a more precise risk assessment should be performed

    .
    In this real cohort study, higher levels of FAR and DM were associated with poorer 5-year outcomes in patients with coronary artery disease undergoing PCI
    .
    The level of FAR may help identify high-risk individuals in this particular population, where a more precise risk assessment should be performed

    .

    Original source: Wang P, Yuan D, Zhang C, et al.
    High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort.
    Cardiovasc Diabetol 2022 Mar 21;21(1) 

    Original source: Wang P, Yuan D, Zhang C, et al.
    High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort.
    Cardiovasc Diabetol 2022 Mar 21;21(1) 
    High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort.
    Leave a


    comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.